BreathEazy has just formed a strategic alliance with Henry Schein, the largest veterinary wholesaler in Europe. With the worldwide awareness of the Aero range of veterinary products and their effectiveness in treating respiratory disease, veterinarians Europe wide now have overnight access to these products. For a current list of veterinary distributors of the Aero range of products, please click here (veterinarians only)
Breatheazy is delighted to announce a new partnership with VetMan in Finland who will be distributing the Aero range of products. This new distributor in Finland means that BreathEazy now has a presence in thirteen countries world wide.
Following extensive testing and research, the AeroKat and AeroDawg aerosol chambers have been improved with the following features: -
![]() |
|
| AeroHippus equine system | |
Additionally we are delighted to announce the launch of a new product, the AeroHippus equine system. This cost effective alternative to the AeroMask equine system boasts the following features: -
Download product brochures: -
(You will need Adobe Acrobat - get it here)
BreathEazy is delighted to announce a new strategic partnership with CentraVet, the premier veterinary wholesaler in France.
Nick Bexfield et al discuss the value of inhaled corticosteroids in the management of chronic inflammatory airway disease in dogs.
Click here to read more...
Carol R Reinero et al. discuss the effects of inhaled flunisolide on both the hypothalamic-pituitary adrenocortical axis and the systemic immune system.
Read the abstract here...
R.A. Hirt presents a comprehensive review of both the current understanding and treatment protocols of feline asthma. The article also goes on to discuss current research into the disease and gives a preview of future therapeutics.
Click here to read more...
Nick Bexfield BVetMed CertSAM MRCVS from Queen's Veterinary School, Cambridge University gives a case presentation on a four year old cat with feline asthma.
Read the full article (220Kb) here...
Masoli et al discuss the use of a long acting beta agonist (salmeterol) in providing 24 hour bronchodilation for human asthma patients. Their conclusion was that the single evening administration of salmeterol resulted in a duration of bronchodilation of at least 24 h, with the abolition of the accentuated biphasic circadian variation in airway tone observed in asthma.
Read the abstract here...
Masoli, Weatherall, Holt and Beasley from the Medical Institute of New Zealand discuss the use of a long acting beta agonist in conjunction with inhaled corticosteroids in symptomatic human asthma patients. Their conclusion is that the addition of a LABA (salmeterol) to moderate doses of a ICS (fluticasone) results in a significantly greater clinical benefit than increasing the dose of ICS by twofold or more.
Read the abstract here...